The Business Research Company’s report on the Fatty Acid Oxidation Disorders (FAODs) Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
Which emerging drivers are set to accelerate the growth of the fatty acid oxidation disorders (faods) market further?
The increasing demand for gene therapy is expected to propel the growth of the fatty acid oxidation disorders (FAODs) market going forward. Gene therapy refers to a medical technique that involves modifying or replacing defective genes to treat or prevent diseases. The increasing demand for gene therapy is attributed to its potential to treat genetic disorders, cancer, and rare diseases by targeting the underlying genetic causes, leading to significant investments and advancements in biotechnology. Gene therapy seeks to correct metabolic deficiencies caused by fatty acid oxidation disorders by delivering functional genes, restoring enzymatic activity, enhancing energy production, and preventing disease complications. For instance, in April 2024, according to the American Society of Gene & Cell Therapy, a US-based organization for gene and cell therapy, in the fourth quarter, the number of gene therapies in Phase III clinical trials increased by 10%, marking the first quarterly growth of this kind since the third quarter of 2022. Therefore, the increasing demand for gene therapy is driving the growth of the fatty acid oxidation disorders (FAODs) market.
Access Your Free Sample of the Global Fatty Acid Oxidation Disorders (FAODs) Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=21964&type=smp
What are the key factors influencing the forecasted market size of the fatty acid oxidation disorders (faods) industry?
The fatty acid oxidation disorders (FAODs) market size has grown strongly in recent years. It will grow from $9.55 billion in 2024 to $10.33 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to increased awareness, rise in prevalence of rare and genetic disorders, increasing number of product approvals, increased government initiatives, and rising demand for orphan drugs.
The fatty acid oxidation disorders (FAODs) market size is expected to see strong growth in the next few years. It will grow to $13.99 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to expanding need for sustainable bio-products, increasing adoption of personalized medicine, early diagnosis of FAODS, increasing funding for research and development, and increasing focus on improving long-term outcomes. Major trends in the forecast period include integration of telehealth services, use of artificial intelligence in diagnostics and drug discovery, advancements in genetic testing, advancements in technology, and shift towards patient-centric care models.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=21964&type=smp
Who are the leading competitors in the fatty acid oxidation disorders (faods) market?
Major companies operating in the fatty acid oxidation disorders (FAODs) market are BASF SE, Thermo Fisher Scientific Inc, Takeda Pharmaceutical Company Limited, Baxter International Inc, Koninklijke DSM NV, Ingredion Incorporated, Lonza Group Ltd, Roquette Frères SA, Dr Reddy’s Laboratories Limited, Tate & Lyle PLC, ANI Pharmaceuticals Inc, Ultragenyx Pharmaceutical Inc, Gulshan Polyols Limited, Hubei Guangji Pharmaceutical Co Ltd, Omega Laboratories Limited, Actiza Pharmaceutical Private Limited, Allmpus Laboratories Private Limited, Reneo Pharmaceuticals Inc, Greenwell Lifesciences, NB Group Co Ltd.
Which emerging trends are set to transform the fatty acid oxidation disorders (faods) market landscape?
Major companies operating in the fatty acid oxidation disorders (FAODs) market are focusing on developing innovative solutions such as peroxisome proliferator-activated receptor delta (PPARd) agonists to enhance metabolic control and improve treatment outcomes for patients with FAODs. A peroxisome proliferator-activated receptor delta (PPARd) agonist is a substance that activates the PPARd receptor, which is involved in regulating lipid metabolism, inflammation, and energy balance, and may provide therapeutic advantages for metabolic disorders and cardiovascular diseases. For instance, in January 2023, Reneo Pharmaceuticals Inc., a US-based clinical-stage pharmaceutical company, received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its investigational drug, Mavodelpar (REN001), which targets long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency, a genotype associated with long-chain fatty acid oxidation disorder (LC-FAOD). By activating PPARd, Mavodelpar aims to enhance mitochondrial function, improve energy metabolism, and reduce symptoms associated with LC-FAOD.
How do different geographies compare in terms of market share and growth potential in the fatty acid oxidation disorders (faods) market?
Asia-Pacific was the largest region in the fatty acid oxidation disorders (FAODs) market in 2024. The regions covered in the fatty acid oxidation disorders (FAODs) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Order Your Report Now For Swift Delivery
Which major segments of the fatty acid oxidation disorders (faods) market are experiencing the fastest growth?
The fatty acid oxidation disorders (FAODs) market covered in this report is segmented –
1) By Type: Long Chain, Short Chain
2) By Drug Type: Levocarnitine, Dextrose, Riboflavin, Other Drug Types
3) By Route of Administration: Oral, Intravenous
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Stores
5) By End User: Hospitals, Clinics, Pharmaceutical Companies
Subsegments:
1) By Long Chain: Very Long-Chain Acyl-CoA Dehydrogenase Deficiency (VLCAD), Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency (LCHAD), Trifunctional Protein Deficiency (TFP), Carnitine Palmitoyltransferase II Deficiency (CPT II)
2) By Short Chain: Medium-Chain Acyl-CoA Dehydrogenase Deficiency (MCAD), Short-Chain Acyl-CoA Dehydrogenase Deficiency (SCAD), Carnitine Uptake Defect (CUD)
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21964
How is the fatty acid oxidation disorders (faods) market defined, and what are its core characteristics?
Fatty acid oxidation disorders (FAODs) are a group of rare genetic metabolic disorders that impair the body’s ability to convert fats into energy due to a deficiency or absence of specific enzymes required for fatty acid breakdown. Fatty acid oxidation disorders lead to an accumulation of fatty acids in the body, which can cause severe energy deficiency, hypoglycemia, muscle weakness, and potential organ damage, particularly during periods of fasting or illness.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
